Kornimate/medical-research-clean huggingface dataset:
cormet large diameter metal on metal (ldmom) total hip system (g030265)

Conditions: Osteoarthritis; Rheumatoid Arthritis; Avascular Necrosis

Summary: to demonstrate the safety and efficacy of the cormet large diameter metal on metal (ldmom) total hip system using a composite clinical success (ccs) primary endpoint.

the results from the cormet large diameter metal on metal (ldmom) total hip system cohort will be compared to the historical results from a ceramic on ceramic (coc) hip system cohort. the primary endpoint clinical composite success (ccs) criterion at 24 months postoperative is based on a harris hip score ≥ 80 and the absence of any revision,replacement, or modification of any study component.

Eligibility criteria:
inclusion criteria: patient: * is skeletally mature * is mentally capable of completing follow-up forms * will be available for follow-up out to 2 years * has a preoperative harris hip score \<70 points * has been deemed a candidate for hip replacement by diagnosis of the investigator. exclusion criteria: patient: * has active joint infection * has had previous hip arthrodesis (fusion) * has had above knee amputation of either extremity * has active neoplastic disease * has a need for a structural bone graft in the operative side * has an ipsilateral hemi or total arthroplasty of any kind * has a nonunion or malunion of any part of the femur on operative side * has severe osteoporosis of the pelvis and/or femur as noted on standard radiograph * is a prisoner * is pregnant * is known to be allergic to implant materials * is morbidly obese.

Keywords: arthritis
studying genes associated with non-hodgkin lymphoma in young patients

Conditions: Childhood Burkitt Lymphoma; Childhood Lymphoblastic Lymphoma

Summary: this research studies genes associated with non-hodgkin lymphoma in young patients. studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer

objectives: i. to conduct a preliminary investigation of the effects of loci strongly and consistently associated in prior genome-wide association studies (gwas) and validation studies of childhood/adolescent acute lymphoblastic leukemia (all), adult non-hodgkin lymphoma (nhl), autoimmune diseases, and atopic diseases on the risk of nhl (lymphoblastic and burkitt lymphomas) in children and adolescents. outline: dna samples are analyzed by single nucleotide polymorphism and genotyped by fluorogenic polymerase chain reaction (pcr)-based allelic discrimination (taqman) assays using the abi prism 7900ht reverse transcriptase (rt)-pcr system.

Eligibility criteria:
inclusion criteria: * slides and/or other available specimens from patients diagnosed with lymphoblastic lymphoma (ll) or burkitt lymphoma ( bl) enrolled on the children oncology group (cog) protocols 5961, a5971, and anhl01p1 collected at the time of diagnosis and currently housed at the biopathology center at nationwide children's hospital * samples from non-hispanic white patients * dna samples from 384 healthy, anonymous, non-hispanic white blood donors used as controls * see disease characteristics * not specified
sars-cov-2 (covid-19) longitudinal study: understanding susceptibility, transmission and disease severity (legacy study)

Conditions: SARS-CoV Infection

Summary: the study aims to investigate sars-cov-2 susceptibility, transmission and disease severity in healthcare workers and patients. residual specimens from an existing collection of samples in viral inactivating buffer and derivatives and serum from the crick covid-19 consortium testing centre (cohort a1) and additional biological material collected prospectively (cohorts a2 and b) will be used for research into sars-cov-2 transmission, evolution and immune control. this testing centre is a partnership between uclh and the francis crick institute to provide covid 19 rt pcr testing for healthcare workers (hcws) and patients in london hospitals and care homes. a third group (cohort c) of the study will allow for collaborative work with other rec approved research studies that have used the crick covid-19 consortium testing centre and will involve the use of study samples already collected from each study to be analysed under the sars-cov-2 longitudinal study end points


Eligibility criteria:
inclusion criteria: * individuals who have previously provided nasal throat swab samples for sars-cov-2 testing at the crick covid 19 consortium testing centre. * ≥18 years of age * to enrol in the sars-cov-2 positive cohort of the study, the participant should have a positive rt qpcr result * employees based at the participating sites including who had their serology and/or swab tested (for recruitment to cohort b) * participants enrolled in other studies who had their samples processed by using the crick covid 19 consortium testing centre (for recruitment to cohort c). * written informed consent (except cohort a1)
study of m5049 in participants with covid-19 pneumonia (anemone)

Conditions: Coronavirus Disease 2019

Summary: the study will evaluate the safety and efficacy of orally-administered m5049 in coronavirus disease 2019 (covid-19) pneumonia participants who are hospitalized but not on mechanical ventilation.


Eligibility criteria:
inclusion criteria: * participant provides signed informed consent prior to the initiation of any study assessments * has laboratory-confirmed sars-cov-2 infection as determined by nucleic acid amplification test, polymerase chain reaction, antigen test or other commercial or public health assay (based on locally acceptable accepted guidelines) in a sample collected less than (\<)10 days prior to randomization * has chest imaging consistent with covid-19 pneumonia (as per locally accepted guidelines) if chest imaging is not available during screening, please discuss with medical monitor or designee regarding evidence of probable covid-19 pneumonia for study participant eligibility * not on mechanical ventilation or ecmo * has an spo2 less than (\ =) 150 (or equivalent spo2/fio2 \>=190) with a maximum fio2 0.4 if participant is on chronic low oxygen therapy (less than or equal to 2 liter), assess their current baseline oxygen requirements for eligibility * requires hospitalization * other protocol defined inclusion criteria may apply exclusion criteria: * any condition that could interfere with the study objectives, conduct or evaluation in the opinion of the investigator or sponsor or designee * significantly uncontrolled medical illness (eg, cardiovascular disease, hypertension, diabetes mellitus, obstructive lung disease, neurological associated with seizures (example: cerebrovascular accident/stroke, acute brain infection, traumatic brain injury, progressive brain disease, congenital brain disease or neuropsychiatric disorder) * known active infection other than covid-19 * pregnancy or breastfeeding * other protocol defined exclusion criteria may apply

Keywords: covid-19 severe acute respiratory syndrome coronavirus-2 (sars-cov-2)
the safety of cataract removal by phacoemulsification surgery in patients under anti-aggregant and coumadin treatment

Conditions: Efficacy; Complications

Summary: to assess the risks of intra- and postoperative bleeding tendency associated with cataract surgery by phacoemulsification in patients on coumadin and antiaggregant treatments. design: consecutive prospective study.

to assess the risks of intra- and postoperative bleeding tendency associated with cataract surgery by phacoemulsification technique in patients on coumadin and antiaggregant treatment design: consecutive prospective study.

Eligibility criteria:
inclusion criteria: * patients who give informed consent to participate in the study exclusion criteria: * single eye complicated cataract

Keywords: cataract, phacoemulsification, coumadin, antiaggregants
development of a new non-radioactive test for measuring glomerular filtration rate using the tetrapeptide n-acetyl-ser-asp-lys-pro-amide (acsdkp-nh2)

Conditions: Healthy; Chronic Kidney Disease

Summary: the purpose of the study is to validate a new reference marker for evaluation of renal function (glomerular filtration rate).

chronic kidney disease (ckd) is a worldwide public health problem with an increasing incidence and prevalence, poor outcomes (kidney failure, complications of decreased kidney function and cardiovascular disease), and high cost. some of the adverse outcomes can be prevented or delayed by early detection and treatment. however, ckd is frequently underdiagnosed and undertreated. the glomerular filtration rate (gfr) is considered as the best index of renal function. the clinical action plan promoted by international guidelines groups refers to gfr values. despite recent improvements, prediction equations developed in order to estimate gfr elicit a huge lack of accuracy when considering the individual patient, especially in case of early ckd. rigorous assessment of gfr requires the measurement of urinary or plasma clearance of an ideal exogenous filtration marker which is either non-radioactive (inulin, iothalamate, or iohexol) or radioactive ( 51cr-edta or 99mtc dtpa. measuring clearance with the use of exogenous markers is difficult to perform in clinical practice because it is expensive and cumbersome and needs specialised laboratories and thus, is underused. there is an unmet need for the development of a new non-radioactive gfr tracer that could combine both the analytical accuracy of radioactive tracers and the simplicity of its measurement. such a tracer should improve clinical care and follow-up of patients.

Eligibility criteria:
inclusion criteria: * phase i: 18-35 years male * phase i: healthy volunteers * phase ii: 18-80 years patients (both sex) * phase ii: with chronic kidney disease exclusion criteria: * phase i: smokers * phase i: allergic

Keywords: chronic kidney disease gfr inulin 51cr-edta asdkp-nh2 healthy male 18-35 yrs old, non smokers, non allergic or male/female 18-80 yrs old with chronic kidney disease
development of a cough control questionnaire (ccq)

Conditions: Cough

Summary: chronic cough (\>8 weeks in duration) affects 5-12% of the global population, and is associated with considerable health status impairment and comorbidities. currently, there are validated severity and impact outcome measures whilst objective measures with cough frequency monitoring is not available in routine clinical practice. unlike other chronic respiratory diseases, namely asthma, there are no validated dedicated tools to assess the control of cough as a disease. this study aims to develop a validated patient-focused tool to assess the control of cough, which may be useful to evaluate the benefit and value of treatments in both clinical and research settings.

this study will involve 3 phases: * phase 1: literature review. review of currently available validated tools to assess control in respiratory diseases. * phase 2: development of cough control questionnaire (ccq). patient focus groups will aid development of a conceptual framework of cough control and ensure content validity through qualitative research methods including thematic analysis. expert panel review of cough control framework will also be undertaken. ccq item development will be grounded in patient focus groups and expert review findings, and reviewed through cognitive debrief with patients. * phase 3: validation of ccq. prospective consecutive patients with chronic cough will complete ccq, cough severity assessments and health status assessments. patients will be invited to undergo objective cough frequency monitoring and cough challenge testing.

Eligibility criteria:
inclusion criteria: * adult patients aged 18 and over with acute and chronic cough (including refractory chronic cough and unexplained chronic cough) and able to read and write in english. a smaller number (n =20) of healthy volunteers will also be included with no evidence of significant respiratory disease. exclusion criteria: * current smokers (or smoking within the last 12 months), respiratory tract infection within the last 4 weeks, use of angiotensin converting enzyme inhibitors (acei), and pregnancy

Keywords: patient-reported outcomes cough control questionnaire
muscle isometric contraction for the treatment of knee osteoarthritis

Conditions: Knee Osteoarthritis (Knee OA)

Summary: this study compares the effects of three different intensities of muscle isometric contraction (mic) on balance ability, proprioception, muscle strength, koa symptoms, and inflammatory factors in synovial fluid among elderly individuals with knee osteoarthritis (koa).

a total of 120 elderly individuals with knee osteoarthritis (koa) will be recruited and randomly assigned into four groups using a digital randomization method: low-intensity group (n = 30), medium-intensity group (n = 30), high-intensity group (n = 30), and control group (n = 30). the elderly individuals in the low-, medium-, and high-intensity groups will receive five interventions per week targeting the quadriceps femoris muscle. for each intervention, the quadriceps will perform an isometric contraction and relaxation for 1 second each. the low-, medium-, and high-intensity groups will perform 10, 20, and 30 repetitions per set, respectively, of muscle isometric contraction (mic) (guided by a rhythmic timer), completing a total of 10 sets with a 30-second rest between sets. the entire intervention will last for 16 weeks. researchers will follow up with participants weekly to complete exercise record forms, ensuring that all subjects maintain their original lifestyle and dietary habits. the study aims to compare the effects of three different intensities of mic on balance ability, proprioception, muscle strength, koa symptoms, and inflammatory factors in synovial fluid among elderly individuals with koa.

Eligibility criteria:
inclusion criteria: * women aged 60 to 80 years; * based on the diagnostic criteria for knee osteoarthritis (koa) established by the american college of rheumatology in 2001, participants with koa graded 1 to 3 were selected; * compliance with the declaration of helsinki and signing of the informed consent form. exclusion criteria: * cardiovascular diseases; * need for surgery or pharmacological treatment in the near future; * neuromuscular diseases; * currently engaged in regular exercise.

Keywords: koa muscle isometric contraction
genes and phenotype (gap) a national resource for genotype-phenotype studies of immunological and inflammatory pathways

Conditions: Immune System Diseases

Summary: the purpose of this study is to enrol generally healthy adults, who are asked to provide a blood sample, to study how the immune system works.

the primary purpose of this research is to develop a better understanding of how the immune system works. by studying immune function in many people, we will be able to determine the range of normal variation. the second purpose is to enroll people who are willing to serve as comparisons in future research studies into the genotype and phenotype research registry (gap registry). volunteers are asked to provide information on age, ethnicity and medical history. volunteers are asked to provide a blood sample of up to 100cc and allow us to contact you about additional studies.

Eligibility criteria:
inclusion criteria: * over age 18 * generally healthy exclusion criteria: * history of autoimmune disease * history of chronic immunodeficiency or chronic viral infections such as epstein barr virus, hepatitis or hiv * currently undergoing treatment for cancer * current treatment with immuno-suppressant drugs * pregnancy
qualitative research for stage 4 stomach cancer and their caregivers

Conditions: Stage 4 Stomach/Gastric Cancer; Patients and Caregivers

Summary: find a cure panel is looking for people with stage 4 stomach/gastric cancer or the caregivers of people with stage 4 stomach/gastric cancer to participate in anonymous and qualitative research that will take an estimated 60 minutes of your time. this is opinion based, experiential research and is not a drug trial. note that stage iv is also known as "advance disease" or metastatic stomach/gastric cancer. if you are interested in participating, please email facp at: info@findacurepanel.com


Eligibility criteria:
inclusion criteria:stage 4 stomach cancer patients and caregivers - exclusion criteria:loved one must still be living -

Keywords: stage 4 stomach cancer stage 4 gastric cancer
study of latent tuberculosis infection (ltbi) by high resolution scanner

Conditions: Tuberculosis

Summary: it is traditionally considered that someone with a positive tuberculin skin test (tst) (and/or positive result in cell interferon-gamma release assay (tigra), depending on the different countries' guidelines) is infected but not ill when the absence of lesions is demonstrated in a thorax x-ray assay. even though, the experiences described in literature using cows and pigs as animal models for the study of ltbi demonstrate the presence of this kind of lesion in the animals, even too small to be detected by x-ray assay, which would suggest they also could happen in human ltbi. nowadays, the high resolution scanners (hr tc) offer the possibility of detecting any lesion approximately 1 mm in diameter, so the investigators plan to use this technique to screen people already infected by m. tuberculosis (but not ill, following the diagnosis standard guidelines). additional pathological analysis of resected and post-mortem tissues will provide lesion-based profiles of humans infected with tuberculosis.

it is traditionally considered that the development of ltbi is due to the m. tuberculosis ability to develop a dormancy state within well-structured lesions (granulomas), which can remain in the lung of the host even for life. the investigators have developed a new original hypothesis based on scientific evidence that takes into account the idea that a lesion cannot be held forever, because the host tends to remove any lesion in order to rebuild the original parenchyma, in a healing process. even if m. tuberculosis can remain in a dormant/non-replicating state for a long period, this is an important but not sufficient factor to explain the ltbi. the dynamic hypothesis tries to explain the existence of ltbi in spite of the healing process that could remove it by a constant reinfection of the host's tissue.

Eligibility criteria:
inclusion criteria: * people with tst+ (plus positive tigra result, if possible) and normal thorax x-ray assay (normal as absence of any detectable lesion) exclusion criteria: * active tb * any medical condition or illness that could compromise the volunteer's health if entering the project

Keywords: latent tuberculosis infection high resolution scanners dynamic hypothesis of latent tuberculosis infection
acute effects of satiostat ingestion on satiation hormones, gastric emptying, subjective feelings of appetite and energy intake

Conditions: Obesity

Summary: satiostat is a composition comprising a specific dietary fibre component (a mixture of hydrocolloids with excellent safety profiles and a long history of use in humans) and a lipid component (long-chain fatty acids). the goal of this combination is to achieve long-acting delivery of long-chain fatty acids to the intestinal lining, triggering the sustained release of satiety-signals from intestinal cells, and consequently reducing appetite and lowering food intake in humans. effects of acute ingestion of satiostat vs. a control will be examined. on a first and second study day, volunteers receive a preload of either satiostat or a control and then an oral glucose load of 75g enriched with c13 sodium acetate. gastric emptying will be measured by means of a breath test, and insulin, glucose and satiation hormones will be assessed. on the third and fourth study day, volunteers receive a preload of either satiostat or a control and are then presented a test meal. total calorie intake is measured as well as subjective feelings of satiation. in addition satiation hormones are measured.


Eligibility criteria:
inclusion criteria: * obese volunteers (bmi \> 30kg/m2) * otherwise healthy * informed consent as documented by signature (appendix informed consent form) exclusion criteria: * food allergies, food intolerance * evidence of relevant cardiovascular, pulmonary, renal, hepatic, pancreatic, gastrointestinal, metabolic, endocrinological, neurological, psychiatric or other diseases at screening * chronic or clinically relevant acute infections * clinically relevant abnormalities in chemical, haematological or any other laboratory parameters * participation in drug trials within 2 months before start of the study * neurological or psychiatric disease or drug or alcohol abuse, which would interfere with the subjects proper completion of the protocol assignment * pregnancy: although no contraindication pregnancy might influence metabolic state. women who are pregnant or have the intention to become pregnant during the course of the study are excluded. in female participants of childbearing age not using safe contraception (oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices) a urine pregnancy test is carried out upon screening. * antibiotic therapy within the last 3 months before inclusion * substance abuse, alcohol abuse * inability to follow procedures due to psychological disorders, dementia or insufficient * knowledge of project language (german). * participation in another study with investigational drug within the 30 days preceding and during the present study.
bone marrow aspirate concentrate in treating mandibular cystic defects

Conditions: Mandible Cyst

Summary: mandibular cystic defect healing is a complex process. various methods have been developed to shorten the bone regeneration time and improve its quality. autogenous grafting is the gold standard for filling cystic defects due to the osteogenesis property provided by the viable cells but is related to donor site morbidity. allografts and xenografts are used for the same purpose. however, the increased cost is their main disadvantage. bone marrow aspirate concentrate is now used to enhance the healing and regeneration process in many areas of the body with no morbidity and low cost.


Eligibility criteria:
inclusion criteria: * patients suffering from mandibular cystic defect. * cystic defect width of 4-8 cm that requires removal under general anesthesia. exclusion criteria: * medically compromised patients contradicting operation. * previously enucleated lesions. * previous surgery, tumor, infection to the pelvis affecting the anterior iliac crest. * infected cysts